| Bid Price | High Price | ||
|---|---|---|---|
| Ask Price | Low Price | ||
| Open Price | Spread | ||
| Prev Close | Volume |
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Dec 6, 2019 | 7,260.00 | 7,279.00 | 7,209.00 | 7,258.00 | 2,117,281 |
| Dec 5, 2019 | 7,341.00 | 7,353.00 | 7,221.00 | 7,229.00 | 1,947,949 |
| Dec 4, 2019 | 7,313.00 | 7,320.00 | 7,213.00 | 7,313.00 | 3,335,482 |
| Dec 3, 2019 | 7,425.00 | 7,425.00 | 7,272.00 | 7,334.00 | 3,766,553 |
| Dec 2, 2019 | 7,451.00 | 7,526.00 | 7,391.00 | 7,422.00 | 3,438,418 |
| Name | AstraZeneca | Epic | AZN |
|---|---|---|---|
| ISIN | GB0009895292 | Currency | GBX |
| Type | Equity | Trading Segment | SET1 |
| Record Status | Active | Trading Status | Closed |
| Industry | Health Care | Sector | Pharmaceuticals |
| EMS | 300 | Prev Close | 7,258.00 |
| Shares in Issue (m) | 1,311.91 | Market Cap (£m) | 94,838.21 |
| PE Ratio | 42.52 | Div per Share (p) | 215.20 |
| Div Yield | 3.03 | Div Cover | 0.78 |
| EPS | 170.00 | EPS Growth (%) | -28.27 |
| PEG | -1.50 | DPS Growth (%) | 6.27 |
| ROCE | 4.49 | Net Gearing | 68.88 |
| Quick Ratio | 0.78 | Current Ratio | 0.96 |
| Date | Broker | Recomm. | Price | Old Target | New Target | Notes |
|---|---|---|---|---|---|---|
| 06 Dec | Barclays Capital | Overweight | 7,258.00 | 8,300.00 | - | Reiterates |
| 05 Dec | Shore Capital | Buy | 7,258.00 | - | - | Reiterates |
| 03 Dec | UBS | Sell | 7,258.00 | 5,800.00 | - | Unchanged |
| 29 Nov | Shore Capital | Buy | 7,258.00 | - | - | Reiterates |
| 27 Nov | HSBC | Reduce | 7,258.00 | 6,235.00 | - | Reiterates |
| Date | Director | Type | Volume / Price | Trade Value |
|---|---|---|---|---|
| 08 May 2019 | Marc Dunoyer | Buy | 8,500 @ 5,800.00p | £493,000.00 |
| 02 May 2019 | Pascal Soriot | Buy | 17,100 @ 5,825.00p | £996,075.00 |
| 02 May 2019 | Philip Broadley | Buy | 520 @ 5,738.00p | £29,837.60 |
| 01 May 2019 | Pascal Soriot | Buy | 17,100 @ 5,825.50p | £996,160.50 |
| 01 May 2019 | Philip Broadley | Buy | 520 @ 5,738.00p | £29,837.60 |
